ArticleThe American journal of pathology2011
Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.
Article in The American journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 143 citations in OpenAlex.
- Trial
- Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.Cancer cell · 2014Trial
- FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors.The Journal of clinical investigation · 2026Article
- Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment.Discover oncology · 2026Article
- Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth.iScience · 2026Article
- Ureter development and associated congenital anomalies.Nature reviews. Nephrology · 2025Review
- Epithelial and mesenchymal compartments of the developing bladder and urethra display spatially distinct gene expression patterns.Developmental biology · 2025Article
- p63: A Master Regulator at the Crossroads Between Development, Senescence, Aging, and Cancer.Cells · 2025Review
- TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma.BMJ oncology · 2025Article
- Eosinophilic inflammation that begins in the juvenile stage causes hydronephrosis and urothelial cancer in mutant mice.Scientific reports · 2024Article
- Uncommon presentation of transitional cell carcinoma: A case report of hand involvement.Clinical case reports · 2024Article
- Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.Cell reports · 2024Article
- A renal aplasia case mimicking radiologically as unilateral renal agenesis in a child with spina bifida, atresia ani and unilateral undescended testis: a case report.Journal of medical case reports · 2024Article
- The urothelial gene regulatory network: understanding biology to improve bladder cancer management.Oncogene · 2024Review
- A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer.iScience · 2023Article
- Article
- FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer.Communications biology · 2023Article
- Chronic Arsenic Exposure Upregulates the Expression of Basal Transcriptional Factors and Increases Invasiveness of the Non-Muscle Invasive Papillary Bladder Cancer Line RT4.International journal of molecular sciences · 2022Article
- Barrier-Forming Potential of Epithelial Cells from the Exstrophic Bladder.The American journal of pathology · 2022Article
- Development, regeneration and tumorigenesis of the urothelium.Development (Cambridge, England) · 2022Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedHuaiShen, Tian [corrected to Shen, Tian Huai]
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
The TP63 gene, a member of the TP53 tumor suppressor gene family, can be expressed as at least six isoforms due to alternative promoter use and alternative splicing. The lack of p63 isoform-specific antibodies has limited the analysis of the biological significance of p63. We report a novel set of well-defined antibodies to examine p63 isoforms in mouse and human urothelium during embryogenesis and tumor progression, respectively. We provide evidence that basal and intermediate urothelial cells express p63 isoforms, with the TAp63 variant the first to be detected during development, whereas umbrella cells are characterized by a p63-negative phenotype. Notably, we report that p63-null mice develop a bladder with an abnormal urothelium, constituted by a single layer of cells that express uroplakin II and low molecular weight cytokeratins, consistent with an umbrella cell phenotype. Finally, analysis of 202 human bladder carcinomas revealed a new categorization of invasive tumors into basal-like (positive for ΔNp63 and high molecular weight cytokeratins and negative for low molecular weight cytokeratins) versus luminal-like (negative for ΔNp63 and high molecular weight cytokeratins and positive for low molecular weight cytokeratins) phenotypes, with ΔNp63 expression associated with an aggressive clinical course and poor prognosis. This study highlights the relevance of p63 isoforms in both urothelial development and bladder carcinoma progression, with ΔNp63 acting as an oncogene in certain invasive bladder tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.